Todos Medical Ltd.: management transactions · United States · SEC (Form 4)

About Todos Medical Ltd.

Todos Medical Ltd. is a U.S.-reporting healthcare company followed by investors through SEC disclosures, including Form 4 insider transaction filings. In a NYSE/NASDAQ framing, it should be viewed not as a large listed healthcare platform but as a small-cap, highly speculative diagnostics and life-sciences name with limited scale and a strong reliance on financing, partnerships, and commercialization execution. The company describes itself as an in vitro diagnostics business focused on developing novel blood tests for early cancer detection and neurodegenerative disorders such as Alzheimer’s disease, alongside the distribution of COVID-19 screening-related solutions. Its portfolio includes the TBIA cancer-screening platform, the Videssa Breast blood test, the LymPro Alzheimer’s blood test, lab-solution offerings, and 3CL protease-inhibitor related assets, including Tollovid and Tollovir. Founded in Rehovot, Israel, Todos Medical says it has offices in New York City, while its website also lists a Tel Aviv address and a U.S. office in New York. That dual footprint reflects an international setup, but also a business model that has depended heavily on external capital and collaboration to move programs forward. The company’s recent history has included partnerships and asset development around Provista Diagnostics, a CLIA/CAP-certified lab in Georgia, and efforts to commercialize blood-based diagnostics and immune-support products. Its public communications emphasize blood-based screening technologies and a broader diagnostic pipeline aimed at cancer and Alzheimer’s, but the company remains an emerging player rather than a category leader. From a competitive standpoint, Todos operates in a crowded and demanding market where diagnostic companies must validate clinical utility, navigate regulatory requirements, and convert R&D into repeatable revenue. The company’s claimed differentiation lies in its blood-based approaches and proprietary technologies, yet its commercial footing remains limited and its risk profile elevated. A key recent event was the December 2023 announcement of insolvency proceedings in Israel, which is highly material for fundamental investors and underscores the company’s financial stress and going-concern risk. That development should be treated as a central part of any SEO-ready investor description. For French-speaking investors, Todos Medical Ltd. is best characterized as a U.S.-linked healthcare micro-cap with scientific optionality, international operations, and a very high risk/reward profile rather than a mature NYSE/NASDAQ healthcare franchise.